CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Home Allergan granted marketing authorization by FDA for TrueTear
News
25 Apr 2017

Allergan granted marketing authorization by FDA for TrueTear

First-of-its-kind product further adds to Allergan's robust eye care portfolio.

The first intranasal neurostimulating device proven to temporarily increase tear production.

Allergan has been granted marketing authorization from the FDA for TrueTear intranasal tear neurostimulator, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients.

TrueTear is a handheld stimulator with daily disposable tips that is inserted into the nasal cavity to induce the production of tears. There have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.

"TrueTear represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production," said David Nicholson, Chief R&D Officer, at Allergan. "As an innovator in eye care, we are continually looking for new products to offer through our portfolio, and TrueTear represents the next step forward."

The new advancement is an addition to Allergan's current eye care portfolio. Last May, Allergan announced positive results from two pivotal trials for TrueTear that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.

"In clinical trials, TrueTear demonstrated increased tear production upon stimulation of the nasal cavity," said John Sheppard, professor of Ophthalmology, Eastern Virginia Medical School and president of Virginia Eye Consultants. "Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years. TrueTear is the first of its kind to provide a temporary increase in tear production in this way."